FabioPetroccaMD

Hematologic Oncology

Director, Cellular Therapy Program and Assistant Professor of Medicine, Boston University Chobanian and Avedisian School of Medicine

Dr. Petrocca is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
830 Harrison Ave
# Moakley
Boston, MA 02118
Phone+1 617-638-6428

Fax+1 617-638-5756

PubMed

135 citations
A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells
Fabio Petrocca, Gabriel Altschuler, Shen Mynn Tan, Marc L. Mendillo, Haoheng Yan
Cancer Cell. 2013-08-12
27 citations
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.
Yi Lin, Noopur S Raje, Jesús G Berdeja, David S Siegel, Sundar Jagannath
Nature Medicine. 2023-09-01
1001 citations
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje, Jesus G. Berdeja, Yi Lin, David S. Siegel, Sundar Jagannath
The New England Journal of Medicine. 2019-05-01

Journal Articles

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C Munshi, Larry D Anderson, Deepu Madduri, Sagar Lonial, Noopur Raje, Fabio Petrocca, Kristen Hege, The New England Journal of Medicine

How Boston Is Beating CancerJanuary 24th, 2023
BMC Is Poised to Enter the CAR T-cell Therapy Clinical Trials EcosystemJanuary 12th, 2023